Knight Therapeutics (TSE:GUD) Trading Up 0.6% – Time to Buy?

Knight Therapeutics Inc. (TSE:GUD)’s share price traded up 0.6% during trading on Friday . The stock traded as high as C$5.41 and last traded at C$5.37. 22,259 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 37,893 shares. The stock had previously closed at C$5.34.

Analysts Set New Price Targets

Separately, Raymond James raised shares of Knight Therapeutics to a “moderate buy” rating in a research note on Friday, November 15th.

Knight Therapeutics Stock Up 0.6 %

The stock has a market cap of C$543.50 million, a price-to-earnings ratio of -26.85, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a quick ratio of 1.79, a current ratio of 3.41 and a debt-to-equity ratio of 7.62. The stock has a fifty day moving average of C$5.33 and a two-hundred day moving average of C$5.58.

Insider Activity at Knight Therapeutics

In related news, Director Samira Sakhia purchased 20,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was purchased at an average price of C$5.15 per share, for a total transaction of C$103,000.00. Also, insider Sime Armoyan acquired 90,300 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average price of C$5.13 per share, for a total transaction of C$463,672.44. Company insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.